Company intelligence / Profile preview

CarboHyde

Ownership: Private
Employees: ~24
Development stage: Preclinical

Overview

The company has several preclinical programs in neurodegenerative and rare disease indications. They have generated substantial supporting cellular and animal data for their breast cancer therapeutic (KS-01) and are working on IND submission and clinical trial initiation. Their Alzheimer's disease candidate (CHD-201) has passed proof-of-concept studies in various cellular and animal models[1][3][4].

Therapeutic areas: OncologyRare DiseasesNeurology
Modalities: Cyclodextrin-based APIscarbohydrate-based APIsoligonucleotides
Industry: Biotech

Drug pipeline

3 assets

KS-01

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

University of Witwatersrand (WITS) for KS-01 development

Beyond the preview

Go deeper on CarboHyde.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CarboHyde.

Explore the full profile